secwatch.observer — SEC 8-K summary
======================================

Issuer:     MACROGENICS INC (MGNX)
CIK:        0001125345
Form:       8-K
Filed at:   2023-11-06T23:59:59+00:00
Accession:  0001125345-23-000125
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MacroGenics Q3 net income $17.6M ($0.28 EPS); cash $256.4M; TAMARACK enrollment ahead of schedule
--------------------------------------------------------------------------------

- Net income $17.6M ($0.28 diluted EPS) vs net loss $24.8M in Q3 2022; revenue $10.4M down from $41.7M.
- Cash and marketable securities $256.4M; expect cash runway into 2026; received $15.7M Gilead milestone and $50M Sanofi milestone in Q3.
- Completed enrollment of TAMARACK Phase 2 study of vobra duo ahead of schedule; data readout expected H1 2024.
- Initiated LORIKEET Phase 2 of lorigerlimab in mCRPC; IND submitted for MGC026 ADC; Phase 1 to start Q1 2024.
- R&D expenses $30.1M (down from $48.2M); SG&A $12.4M (down from $15.4M); shares outstanding 62.0M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1125345/000112534523000125/0001125345-23-000125-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1125345/000112534523000125/mgnx-20231106.htm
  HTML page:      https://secwatch.observer/filing/0001125345-23-000125

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer